EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications

Britt W H van der Arend iD, Floor C van Welie iD, Michael H Olsen, Jan Versijpt, Antoinette Maassen Van Den Brink, Gisela M Terwindt

Cephalalgia · 2025-01 · 45 (1)

DOI: 10.1177/03331024241297673 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cephalalgia, online erschienen am 29.01.2025. Verfasst von Britt W H van der Arend und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide, Blood Pressure, Antibodies, Monoclonal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or the CGRP-receptor have revolutionized the prevention of migraine. Despite their effectiveness, worries have surfaced regarding potential unwanted cardiovascular effects linked to the vasodilation function of CGRP, suggesting a potential influence on blood pressure (BP).

Methods

Studies were systematically retrieved from PubMed, Cochrane Database of Systematic Reviews, Web of Science, MEDLINE and EMBASE up to 1 May 2024. We focused on randomized controlled trials and observational cohort or case-control studies examining the impact of anti-CGRP(R)-monoclonal antibodies (mAbs) compared to control treatments on BP in patients with migraine. Two reviewers independently conducted study selection, data extraction and risk of bias assessment.

Results

The literature search yielded 693 articles. After removing duplicates and conducting screening, 22 full-text articles were evaluated, with only four studies meeting the inclusion criteria. Among these, only one study had a low risk of bias and reported elevated BP following initiation of anti-CGRP(R)-mAb treatment.

Conclusions

Although anti-CGRP(R)-mAbs offer substantial benefits for migraine prevention, the potential risk of increased BP requires attention. Despite the current limited evidence, clinicians are urged to monitor BP of migraine patients undergoing treatment with anti-CGRP(R)-mAbs and to remain aware of the increased risk of cardiovascular events in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related PeptideBlood PressureAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor AntagonistsHumans

Stichwörter der Autor:innen

anti-CGRPblood pressuremigrainemonitoringmonoclonal antibodiessafety

Substanzen

Calcitonin Gene-Related PeptideAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Internal Medicine 1, Holbaek Hospital, Holbaek, Denmark.
  • Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Department of Neurology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

ORCID-Profile: Britt W H van der Arend, Floor C van Welie

Zitieren

APA

van der Arend, B. W. H., van Welie, F. C., Olsen, M. H., Versijpt, J., Van Den Brink, A. M., & Terwindt, G. M. (2025). Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications. Cephalalgia, 45(1). https://doi.org/10.1177/03331024241297673

Vancouver

van der Arend BWH, van Welie FC, Olsen MH, Versijpt J, Van Den Brink AM, Terwindt GM. Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications. Cephalalgia. 2025;45(1). doi:10.1177/03331024241297673

BibTeX
@article{vanderArend2025,
  author = {van der Arend, Britt W H and van Welie, Floor C and Olsen, Michael H and Versijpt, Jan and Van Den Brink, Antoinette Maassen and Terwindt, Gisela M},
  title = {Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications},
  journal = {Cephalalgia},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1177/03331024241297673}
}
Kostenlos starten →